Techno Trends
Novartis buys GSK’s cancer drugs for $16 bn in three-part deal
Global pharma major Novartis will acquire GlaxoSmithKline Plc's (GSK) cancer drugs portfolio for $16 billion and sell its vaccines business in return for $7.1 billion, apart from forming a joint venture for the consumer healthcare business in a three-part...
Techno Trends
Biocon Q4 net profit falls 54% to Rs 113 crore
Biotechnology firm Biocon on Friday reported a 54.51 per cent fall in its consolidated net profit at Rs 113.08 crore for the fourth quarter ended March 31, 2014.The company had posted a net profit of Rs 248.61 crore in...
Techno Trends
Lupin forms JV with Japan’s Yoshindo Inc
Drug major Lupin has entered into a joint venture pact with Toyama-based Yoshindo Inc to form a new entity which will be responsible for development as well as obtaining marketing access for products in the Japanese market. ...
Techno Trends
Xenometrix – Mutagenicity Assays and Cytotoxicity Screening Kits
Xenometrix produces and distributes today's most advanced mutagenicity assays and cytotoxicity screening kits designed to help reduce hands-on time, test compound consumption, plastic waste and consequently the cost. Xenometrix has been developing high quality Ames fluctuation...
Techno Trends
Avisoft Bioacoustics – Monitoring Equipment for Mice and Rat Ultrasonic Vocalisations
Avisoft Bioacoustics provides cutting-edge equipment for monitoring mice and rat ultrasonic vocalisations (USV) in drug development procedures and basic research in neuroscience. USV are used as an indicator of the emotional and motivational status in animal models of stress,...
Techno Trends
DNA Electronics Secures Funding From Genting Berhad To Develop Genalysis® Point-of-Care Genomic Diagnostics Product Line
DNA Electronics Ltd (DNAe), a developer of semiconductor solutions for real-time DNA and RNA detection, today announces that it had successfully secured the necessary funding for DNAe to develop the Genalysis® point-of-care genomic diagnostic product line. The majority of...
Techno Trends
Amgen, MGH, Broad Institute to discover new drugs to treat inflammatory bowel disease
Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD). The collaboration...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read